ascopubs.org

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi ...

Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
The American Journal of Managed Care

CA-125 Test Accuracy for Ovarian Cancer Prediction Varies by Ethnicity

The accuracy of the cancer antigen (CA)–125 test in predicting ovarian cancer varies by ethnicity, primarily due to factors like age and comorbidities rather than ethnicity itself. General ...
clinicaladvisor.com

CA-125 Levels Vary by Patient Race at Ovarian Cancer Diagnosis

The likelihood of having an elevated CA-125 level at ovarian cancer diagnosis was lower for American Indian, Asian, or Black patients versus White patients. HealthDay News — Black and American Indian ...
The American Journal of Managed Care

Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

Current CA-125 thresholds may miss ovarian cancer in racially diverse patients, delaying treatment initiation and contributing to health disparities. Original CA-125 studies were conducted on ...
ascopubs.org

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study In addition to HRD/BRCA status, the tumor primary ...